Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
Clinical trial NCT05580354 · UNKNOWN
Trial details
- NCT number
- NCT05580354
- Sponsor
- Ruijin Hospital
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-09
- Primary completion
- 2024-10-09
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.